Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Bladder Cancer, September 2021

Free Subscription


Abstracts

Retrieve all available abstracts of the following 216 articles:
HTML format


 

Single Articles

  1. BALAR AV, Kamat AM, de Wit R
    Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer - Authors' reply.
    Lancet Oncol. 2021;22:e380.
    PubMed    


  2. RENTSCH CA, Hayoz S, Cathomas R
    Pembrolizumab monotherapy for high-risk, non-muscle-invasive bladder cancer.
    Lancet Oncol. 2021;22:e379.
    PubMed    


  3. LI S, Zhang D, Zeng S, Wu T, et al
    Prognostic Value of Preoperative Albumin-to-Fibrinogen Ratio in Patients with Bladder Cancer.
    J Cancer. 2021;12:5864-5873.
    PubMed    
    Abstract available

  4. HIRD AE, Saskin R, Liu Y, Lee Y, et al
    Association between chronic bladder catheterisation and bladder cancer incidence and mortality: a population-based retrospective cohort study in Ontario, Canada.
    BMJ Open. 2021;11:e050728.
    PubMed    
    Abstract available

  5. WU S, Chen X, Pan J, Dong W, et al
    An Artificial Intelligence System for the Detection of Bladder Cancer via Cystoscopy: A Multicenter Diagnostic Study.
    J Natl Cancer Inst. 2021 Sep 2. pii: 6362894. doi: 10.1093.
    PubMed    
    Abstract available

  6. FRAGKOULIS C, Glykas I, Bamias A, Stathouros G, et al
    Novel treatments in BCG failure. Where do we stand today?
    Arch Esp Urol. 2021;74:681-691.
    PubMed    
    Abstract available

  7. KURAMOTO T, Iguchi T, Iba A
    [Solitary Fibrous Tumor of the Urinary Bladder which was Incidentally Found by MRI : A Case Report].
    Hinyokika Kiyo. 2021;67:385-389.
    PubMed    
    Abstract available

  8. PIJPERS OM, Hendricksen K, Mostafid H, de Jong FC, et al
    Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer.
    Urol Oncol. 2021 Aug 29. pii: S1078-1439(21)00337.
    PubMed    
    Abstract available

  9. BAJORIN DF, Collette S, Galsky MD
    Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma. Reply.
    N Engl J Med. 2021;385:957.
    PubMed    


  10. MOLLICA V, Rizzo A, Massari F
    Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma.
    N Engl J Med. 2021;385:956-957.
    PubMed    


  11. CHITIKELA S, Kumar L, Sahoo RK
    Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma.
    N Engl J Med. 2021;385:956.
    PubMed    


  12. ZHENG B, Zhang P, Wang H, Wang J, et al
    Advances in Research on Bladder Cancer Targeting Peptides: a Review.
    Cell Biochem Biophys. 2021 Sep 1. pii: 10.1007/s12013-021-01019.
    PubMed    
    Abstract available

  13. VEERATTERAPILLAY R, Gravestock P, Nambiar A, Gupta A, et al
    Time to Turn on the Blue Lights: A Systematic Review and Meta-analysis of Photodynamic Diagnosis for Bladder Cancer.
    Eur Urol Open Sci. 2021;31:17-27.
    PubMed    
    Abstract available

  14. PORTNER R, Bajaj A, Elumalai T, Huddart R, et al
    A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer.
    Clin Transl Radiat Oncol. 2021;31:1-7.
    PubMed    
    Abstract available

  15. CHATTERJEE A, Bakshi G, Pal M, Kapoor A, et al
    Perioperative therapy in muscle invasive bladder cancer.
    Indian J Urol. 2021;37:226-233.
    PubMed    
    Abstract available

  16. DARDEER KT, Mohammed KA, Hussein TD, Elsheemy MS, et al
    Apolipoprotein A1 as a novel urinary biomarker for diagnosis of bladder cancer: A systematic review and meta-analysis.
    Indian J Urol. 2021;37:217-225.
    PubMed    
    Abstract available

  17. SCHROECK FR, Ould Ismail AA, Perry GN, Haggstrom DA, et al
    Determinants of Risk-Aligned Bladder Cancer Surveillance-Mixed-Methods Evaluation Using the Tailored Implementation for Chronic Diseases Framework.
    JCO Oncol Pract. 2021 Aug 31:OP2100226. doi: 10.1200/OP.21.00226.
    PubMed    
    Abstract available

  18. HUANG S, Bain J, Yiu TW, Gilbourd D, et al
    Accuracy of the Vesical Imaging-Reporting and Data System (VIRADS) for pre-treatment staging of bladder cancer in an Australian cohort.
    J Med Imaging Radiat Oncol. 2021 Aug 29. doi: 10.1111/1754-9485.13317.
    PubMed    
    Abstract available

  19. SAWAZAKI H, Arai Y, Ito Y, Sato K, et al
    Expression of L-Type Amino Acid Transporter 1 is a Predictive Biomarker of Intravesical Recurrence in Patients with Non-Muscle Invasive Bladder Cancer.
    Res Rep Urol. 2021;13:603-611.
    PubMed    
    Abstract available

  20. ZHANG Y, Zhu B, He M, Cai Y, et al
    N6-Methylandenosine-Related lncRNAs Predict Prognosis and Immunotherapy Response in Bladder Cancer.
    Front Oncol. 2021;11:710767.
    PubMed    
    Abstract available

  21. SEGUIER D, Puech P, Kool R, Dernis L, et al
    Multiparametric magnetic resonance imaging for bladder cancer: a comprehensive systematic review of the Vesical Imaging-Reporting and Data System (VI-RADS) performance and potential clinical applications.
    Ther Adv Urol. 2021;13:17562872211039583.
    PubMed    
    Abstract available

  22. ZENG B, Zhao Q, Sun Z, Liu D, et al
    SEC23A Is an Independent Prognostic Biomarker in Bladder Cancer Correlated With MAPK Signaling.
    Front Genet. 2021;12:672832.
    PubMed    
    Abstract available

  23. DAEI S, Ziamajidi N, Abbasalipourkabir R, Khanaki K, et al
    Anticancer Effects of Gold Nanoparticles by Inducing Apoptosis in Bladder Cancer 5637 Cells.
    Biol Trace Elem Res. 2021 Aug 28. pii: 10.1007/s12011-021-02895.
    PubMed    
    Abstract available

  24. GAO J, Shi Y, Zhou D, Zhang Y, et al
    Sarcopenia as an independent predictor for venous thromboembolism events in bladder cancer patients undergoing radical cystectomy.
    Support Care Cancer. 2021 Aug 28. pii: 10.1007/s00520-021-06423.
    PubMed    
    Abstract available

  25. AVIRMED S, Khuanbai Y, Sanjaajamts A, Selenge B, et al
    Modifying Effect of Smoking on GSTM1 and NAT2 in Relation to the Risk of Bladder Cancer in Mongolian Population: A Case-Control Study.
    Asian Pac J Cancer Prev. 2021;22:2479-2485.
    PubMed    
    Abstract available

  26. REXER H, Grimm MO Prof. Dr, Retz M Prof. Dr

    Aktuelle Urol. 2021;52:428-429.
    PubMed    




  27. Aktuelle Urol. 2021;52:412-414.
    PubMed    


  28. YIN D, Jiao W, Li X, Zhao J, et al
    Paraganglioma of the urinary bladder: A case report.
    Asian J Surg. 2021;44:1002-1003.
    PubMed    


  29. TAATJES DJ, Roth J
    In focus in HCB.
    Histochem Cell Biol. 2021;155:525-528.
    PubMed    


  30. YU Z, Xie X, Lu Q, Wang H, et al
    Primary transitional cell carcinoma of the inguinal region: A case report.
    Asian J Surg. 2021;44:788-789.
    PubMed    


  31. KITAZONO T, Tsubouchi K, Ibusuki R, Inoue K, et al
    A Rare Case of Pulmonary Tumor Thrombotic Microangiopathy Associated with Micropapillary Urothelial Carcinoma of the Urinary Bladder: An Autopsy Case.
    Intern Med. 2021;60:2843-2846.
    PubMed    
    Abstract available

  32. WEN CY, Lin JT, Yu CC, Wang CJ, et al
    Non-touch ureteral manipulation of single J ureteral catheterization for robot-assisted cystectomy with intracorporeal ileal conduit.
    Asian J Surg. 2021;44:675.
    PubMed    


  33. HEATH EI, Rosenberg JE
    The biology and rationale of targeting nectin-4 in urothelial carcinoma.
    Nat Rev Urol. 2021;18:93-103.
    PubMed    
    Abstract available

  34. YI W, Yu Y, Li Y, Yang J, et al
    The tumor-suppressive effects of alpha-ketoglutarate-dependent dioxygenase FTO via N6-methyladenosine RNA methylation on bladder cancer patients.
    Bioengineered. 2021;12:5323-5333.
    PubMed    
    Abstract available

  35. KOSKINEN I, Bostrom PJ, Taimen P, Salminen A, et al
    Prediction of neo-adjuvant chemotherapy response in bladder cancer: the impact of clinical parameters and routine biomarkers.
    Scand J Urol. 2021 Sep 9:1-7. doi: 10.1080/21681805.2021.1962403.
    PubMed    
    Abstract available

  36. ASIMAKOPOULOS AD, Colalillo G, Telesca R, Mauriello A, et al
    T1 Bladder Cancer: Comparison of the Prognostic Impact of Two Substaging Systems on Disease Recurrence and Progression and Suggestion of a Novel Nomogram.
    Front Surg. 2021;8:704902.
    PubMed    
    Abstract available

  37. LIANG Y, Ye F, Cheng Z, Ou Y, et al
    Calculated identification of mutator-derived lncRNA signatures of genomic instability to predict the clinical outcome of muscle-invasive bladder cancer.
    Cancer Cell Int. 2021;21:476.
    PubMed    
    Abstract available

  38. MUKHERJEE N, Ji N, Xi T, Lin CL, et al
    Bladder tumor ILC1s undergo Th17-like differentiation in human bladder cancer.
    Cancer Med. 2021 Sep 8. doi: 10.1002/cam4.4243.
    PubMed    
    Abstract available

  39. MORSELLI S, Campi R, Gacci M, Sebastianelli A, et al
    Potential utility of a 4-marker immunohistochemistry panel to predict response to cisplatin-based neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: a single-center preliminary experience.
    Minerva Urol Nephrol. 2021;73:424-427.
    PubMed    


  40. ZENG S, Gao H, Li C, Xing S, et al
    Boosting Photothermal Theranostics via TICT and Molecular Motions for Photohyperthermia Therapy of Muscle-Invasive Bladder Cancer.
    Adv Healthc Mater. 2021 Sep 8:e2101063. doi: 10.1002/adhm.202101063.
    PubMed    
    Abstract available

  41. YAN Y, Cai J, Huang Z, Cao X, et al
    A Novel Ferroptosis-Related Prognostic Signature Reveals Macrophage Infiltration and EMT Status in Bladder Cancer.
    Front Cell Dev Biol. 2021;9:712230.
    PubMed    
    Abstract available

  42. SU Q, Wu H, Zhang Z, Lu C, et al
    Exosome-Derived Long Non-Coding RNAs as Non-Invasive Biomarkers of Bladder Cancer.
    Front Oncol. 2021;11:719863.
    PubMed    
    Abstract available

  43. ZHENG Z, Lai C, Li W, Zhang C, et al
    Identification of a Novel Glycolysis-Related LncRNA Signature for Predicting Overall Survival in Patients With Bladder Cancer.
    Front Genet. 2021;12:720421.
    PubMed    
    Abstract available

  44. PEREIRA FM, Melo MN, Santos AKM, Oliveira KV, et al
    Hyaluronic acid-coated chitosan nanoparticles as carrier for the enzyme/prodrug complex based on horseradish peroxidase/indole-3-acetic acid: Characterization and potential therapeutic for bladder cancer cells.
    Enzyme Microb Technol. 2021;150:109889.
    PubMed    
    Abstract available

  45. PIAO XM, Kang H, Kim WJ, Yun SJ, et al
    Prominence of urinary biomarkers for bladder cancer in the COVID-19 era: From the commercially available to new prospective candidates.
    Investig Clin Urol. 2021;62:500-519.
    PubMed    
    Abstract available

  46. QIU F, Jin Y, Pu J, Huang Y, et al
    Aberrant FBXW7-mediated ubiquitination and degradation of ZMYND8 enhances tumor progression and stemness in bladder cancer.
    Exp Cell Res. 2021 Sep 3:112807. doi: 10.1016/j.yexcr.2021.112807.
    PubMed    
    Abstract available

  47. WU J, Tan Z, Li H, Lin M, et al
    Melatonin reduces proliferation and promotes apoptosis of bladder cancer cells by suppressing O-GlcNAcylation of CDK5.
    J Pineal Res. 2021 Sep 6:e12765. doi: 10.1111/jpi.12765.
    PubMed    
    Abstract available

  48. SOARES LBM, Lima APB, Melo AS, Almeida TC, et al
    Additive effects of resveratrol and doxorubicin on bladder cancer cells.
    Anticancer Drugs. 2021 Aug 27. pii: 00001813-900000000-98278.
    PubMed    
    Abstract available

  49. NI J, Wang K, Zhang H, Xie J, et al
    Prognostic Value of the Systemic Inflammatory Response Index in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Population-Based Study.
    Front Oncol. 2021;11:722151.
    PubMed    
    Abstract available

  50. MURAKI PH, Donin NM
    Ureteritis cystica mimicking upper tract urothelial cancer in a patient with bladder cancer.
    Urol Case Rep. 2021;39:101822.
    PubMed    
    Abstract available


  51. Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment.
    Ont Health Technol Assess Ser. 2021;21:1-123.
    PubMed    
    Abstract available

  52. CUI Y, Zhou Z, Chai Y, Che X, et al
    Identification of a Nomogram from Ferroptosis-Related Long Noncoding RNAs Signature to Analyze Overall Survival in Patients with Bladder Cancer.
    J Oncol. 2021;2021:8533464.
    PubMed    
    Abstract available

  53. WU W, Jia G, Chen L, Liu H, et al
    Analysis of the Expression and Prognostic Value of Annexin Family Proteins in Bladder Cancer.
    Front Genet. 2021;12:731625.
    PubMed    
    Abstract available

  54. FENG C, Pan L, Tang S, He L, et al
    Integrative Transcriptomic, Lipidomic, and Metabolomic Analysis Reveals Potential Biomarkers of Basal and Luminal Muscle Invasive Bladder Cancer Subtypes.
    Front Genet. 2021;12:695662.
    PubMed    
    Abstract available

  55. LIU Z, Tang Q, Qi T, Othmane B, et al
    A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
    Front Immunol. 2021;12:725223.
    PubMed    
    Abstract available

  56. SINGLA N, Margulis V
    Differences between Upper Tract Urothelial Carcinoma and Bladder Cancer.
    AUA News. 2021;26:15-16.
    PubMed    


  57. LIU Y, Lou W, Chen G, Ding B, et al
    Genome-wide screening for the G-protein-coupled receptor (GPCR) pathway-related therapeutic gene RGS19 (regulator of G protein signaling 19) in bladder cancer.
    Bioengineered. 2021;12:5892-5903.
    PubMed    
    Abstract available

  58. ZHANG Z, Sang Y, Liu Z, Shao J, et al
    Negative Correlation Between Circular RNA SMARC5 and MicroRNA 432, and Their Clinical Implications in Bladder Cancer Patients.
    Technol Cancer Res Treat. 2021;20:15330338211039110.
    PubMed    
    Abstract available

  59. SHVERO A, Laufer M, Zilberman DE, Winkler H, et al
    [UPPER TRACT UROTHELIAL CARCINOMA].
    Harefuah. 2021;160:619-624.
    PubMed    
    Abstract available

  60. LUWISCH H, Rabinovich I, Yutkin V, Frank S, et al
    [NEOADJUVANT CHEMOTHERAPY BEFORE RADICAL CYSTECTOMY - MIGHT IT BE OFFERED SELECTIVELY?]
    Harefuah. 2021;160:559-564.
    PubMed    
    Abstract available

  61. ENGELSTEIN D

    Harefuah. 2021;160:556-558.
    PubMed    
    Abstract available

  62. HUNG SY, Chen WF, Lee YC, Su JH, et al
    Rhopaloic acid A induces apoptosis, autophagy and MAPK activation through ROS-mediated signaling in bladder cancer.
    Phytomedicine. 2021;92:153720.
    PubMed    
    Abstract available

  63. SARI H, Celik S, Caglar F, Aktas S, et al
    A candidate antineoplastic herbal agent for bladder cancer: Ankaferd bloodstopper.
    Int J Clin Pract. 2021 Sep 4:e14789. doi: 10.1111/ijcp.14789.
    PubMed    
    Abstract available

  64. SMITH N, Luethcke KR, Craun K, Trepanier L, et al
    Risk of bladder cancer and lymphoma in dogs is associated with pollution indices by county of residence.
    Vet Comp Oncol. 2021 Sep 4. doi: 10.1111/vco.12771.
    PubMed    
    Abstract available

  65. CROOCK R, Modai J, Avda Y, Shpunt I, et al
    Radical Cystectomy after Previous Radiation or Pelvic Surgery: Is It Associated with Increased Morbidity?
    Isr Med Assoc J. 2021;23:545-549.
    PubMed    
    Abstract available

  66. ZHU X, Zhou M, Yu H, Kuang Y, et al
    Bladder paraganglioma managed with transurethral holmium laser resection: A case report.
    Medicine (Baltimore). 2021;100:e26909.
    PubMed    
    Abstract available

  67. KURIWAKI I, Kameda M, Iikubo K, Hisamichi H, et al
    Synthesis and structure-activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency.
    Bioorg Med Chem. 2021;33:116019.
    PubMed    
    Abstract available

  68. RODRIGUEZ PENA MDC, Salles DC, Epstein JI, Canete-Portillo S, et al
    Well-differentiated neuroendocrine tumors of the lower urinary tract: biologic behavior of a rare entity.
    Hum Pathol. 2021;109:53-58.
    PubMed    
    Abstract available

  69. YAMADA T, Toyoda T, Matsushita K, Cho YM, et al
    Expression of stem cell markers as useful complementary factors in the early detection of urinary bladder carcinogens by immunohistochemistry for gamma-H2AX.
    Arch Toxicol. 2021;95:715-726.
    PubMed    
    Abstract available

  70. KNEZ J, Nardelli F, van den Bosch T, Sladkevicius P, et al
    Imaging in gynecological disease: clinical and ultrasound characteristics of urinary bladder malignancies.
    Ultrasound Obstet Gynecol. 2019 Dec 25. doi: 10.1002/uog.21958.
    PubMed    
    Abstract available

  71. HUANG X, Pan T, Yan L, Jin T, et al
    The inflammatory microenvironment and the urinary microbiome in the initiation and progression of bladder cancer.
    Genes Dis. 2020;8:781-797.
    PubMed    
    Abstract available

  72. JIANG Z, Zhang Y, Zhang Y, Jia Z, et al
    Cancer derived exosomes induce macrophages immunosuppressive polarization to promote bladder cancer progression.
    Cell Commun Signal. 2021;19:93.
    PubMed    
    Abstract available

  73. ZHOU BZ, Luo Q, Zhang Y
    Cross-talk and clinical value of m[superscript 6]A regulatory gene in bladder cancer.
    BMC Urol. 2021;21:127.
    PubMed    
    Abstract available

  74. TANG H, Fang T, Ji M, Wang JP, et al
    UBE2S exerts oncogenic activities in urinary bladder cancer by ubiquitinating TSC1.
    Biochem Biophys Res Commun. 2021;578:7-14.
    PubMed    
    Abstract available

  75. MIRZAEI S, Paskeh MDA, Hashemi F, Zabolian A, et al
    Long non-coding RNAs as new players in bladder cancer: Lessons from pre-clinical and clinical studies.
    Life Sci. 2021 Sep 11:119948. doi: 10.1016/j.lfs.2021.119948.
    PubMed    
    Abstract available

  76. SUN X, Chen Q, Zhang L, Chen J, et al
    Exploration of prognostic biomarkers and therapeutic targets in the microenvironment of bladder cancer based on CXC chemokines.
    Math Biosci Eng. 2021;18:6262-6287.
    PubMed    
    Abstract available

  77. NAKAGAWA M, Naiki T, Naiki-Ito A, Ozawa Y, et al
    Usefulness of advanced monoenergetic reconstruction technique in dual-energy computed tomography for detecting bladder cancer.
    Jpn J Radiol. 2021 Sep 13. pii: 10.1007/s11604-021-01195.
    PubMed    
    Abstract available

  78. HE L, Pan X, Wang X, Cao Y, et al
    Rab6c is a new target of miR218 that can promote the progression of bladder cancer.
    Mol Med Rep. 2021;24.
    PubMed    
    Abstract available

  79. ZHOU X, Kurywchak P, Wolf-Dennen K, Che SPY, et al
    Unique somatic variants in DNA from urine exosomes of individuals with bladder cancer.
    Mol Ther Methods Clin Dev. 2021;22:360-376.
    PubMed    
    Abstract available

  80. KOLAT D, Kaluzinska Z, Bednarek AK, Pluciennik E, et al
    Corrigendum: Fragile Gene WWOX Guides TFAP2A/TFAP2C-Dependent Actions Against Tumor Progression in Grade II Bladder Cancer.
    Front Oncol. 2021;11:735435.
    PubMed    
    Abstract available

  81. ZHAO Y, Zhao B, Yan WH, Xia Y, et al
    Integrative Analysis Identified MCT4 as an Independent Prognostic Factor for Bladder Cancer.
    Front Oncol. 2021;11:704857.
    PubMed    
    Abstract available

  82. DONG B, Liang J, Li D, Song W, et al
    Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.
    Front Genet. 2021;12:696912.
    PubMed    
    Abstract available

  83. ZHANG P, Liu Z, Wang D, Li Y, et al
    Scoring System Based on RNA Modification Writer-Related Genes to Predict Overall Survival and Therapeutic Response in Bladder Cancer.
    Front Immunol. 2021;12:724541.
    PubMed    
    Abstract available

  84. KAJAIA D, Kochiashvili D, Muzashvili T, Gachechiladze M, et al
    MOLECULAR CHARACTERISTICS OF THE HETEROGENEITY OF NON-INVASIVE PAPILLARY UROTHELIAL CARCINOMAS AND THE MARKERS OF THEIR RECURRENCE.
    Georgian Med News. 2021;.
    PubMed    
    Abstract available

  85. ZHANG Y, He N, Zhou X, Wang F, et al
    Betulinic acid induces autophagy-dependent apoptosis via Bmi-1/ROS/AMPK-mTOR-ULK1 axis in human bladder cancer cells.
    Aging (Albany NY). 2021;13.
    PubMed    
    Abstract available

  86. TAN P, Cai H, Wei Q, Tang X, et al
    Enhanced chemo-photodynamic therapy of an enzyme-responsive prodrug in bladder cancer patient-derived xenograft models.
    Biomaterials. 2021;277:121061.
    PubMed    
    Abstract available

  87. CHANG E, Apolo AB, Bangs R, Chisolm S, et al
    Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop.
    Nat Rev Urol. 2021 Sep 10. pii: 10.1038/s41585-021-00505.
    PubMed    
    Abstract available

  88. ECKSTEIN M, Kimmel C, Bruendl J, Weber F, et al
    Tumor budding correlates with tumor invasiveness and predicts worse survival in pT1 non-muscle-invasive bladder cancer.
    Sci Rep. 2021;11:17981.
    PubMed    
    Abstract available

  89. ROVIELLO G, Catalano M, Santi R, Palmieri VE, et al
    Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  90. RUSSO GI, Sholklapper TN, Cocci A, Broggi G, et al
    Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  91. KAWANO T, Tachibana Y, Inokuchi J, Kang JH, et al
    Identification of Activated Protein Kinase Calpha (PKCalpha) in the Urine of Orthotopic Bladder Cancer Xenograft Model as a Potential Biomarker for the Diagnosis of Bladder Cancer.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  92. SUH J, Yuk HD, Jeong CW, Kwak C, et al
    Pyuria as a Predictive Marker of Bacillus Calmette-Guerin Unresponsiveness in Non-Muscle Invasive Bladder Cancer.
    J Clin Med. 2021;10.
    PubMed    
    Abstract available

  93. GOMES ATPC, Neves MGPMS, Fernandes R, Ribeiro CF, et al
    Unraveling the Photodynamic Activity of Cationic Benzoporphyrin-Based Photosensitizers against Bladder Cancer Cells.
    Molecules. 2021;26.
    PubMed    
    Abstract available

  94. LOU N, Niu YR, Yang F, Lu ZH, et al
    [Clinicopathological analysis of lung metastatic tumor].
    Zhonghua Bing Li Xue Za Zhi. 2021;50:1039-1044.
    PubMed    
    Abstract available

  95. ZHANG HZ, Wang SY, Dong L, Yang XQ, et al
    [Inflammatory myofibroblastic tumors of the urinary bladder: a clinicopathological study of ten cases].
    Zhonghua Bing Li Xue Za Zhi. 2021;50:1024-1028.
    PubMed    
    Abstract available

  96. LUO HL, Liu HY, Chang YL, Sung MT, et al
    Hypomethylated RRBP1 Potentiates Tumor Malignancy and Chemoresistance in Upper Tract Urothelial Carcinoma.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  97. MURAKAMI K, Kita Y, Sakatani T, Hamada A, et al
    Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer.
    Cancer Sci. 2021;112:3669-3681.
    PubMed    
    Abstract available

  98. SANTOPIETRO AL, Einstein D, Bellmunt J
    Advances in the management of urothelial carcinoma: is immunotherapy the answer?
    Expert Opin Pharmacother. 2021;22:1743-1759.
    PubMed    
    Abstract available

  99. ABD ELWAHAB KM, Desky EAE, Eldery MS, Mohammad FF, et al
    Apparent Diffusion Coefficient Value can Predict Poor Bacillus Calmette-Guerin Responders in T1HG/NMIBC: Prospective Cohort Study.
    Clin Genitourin Cancer. 2021;19:e248-e254.
    PubMed    
    Abstract available

  100. CULINE S, Flechon A, Gravis G, Roubaud G, et al
    Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
    Clin Genitourin Cancer. 2021;19:e216-e222.
    PubMed    
    Abstract available

  101. CHALLAPALLI A, Masson S, White P, Dailami N, et al
    A Single-arm Phase II Trial of Neoadjuvant Cabazitaxel and Cisplatin Chemotherapy for Muscle-Invasive Transitional Cell Carcinoma of the Urinary Bladder.
    Clin Genitourin Cancer. 2021;19:325-332.
    PubMed    
    Abstract available

  102. ESTESO G, Aguilo N, Julian E, Ashiru O, et al
    Natural Killer Anti-Tumor Activity Can Be Achieved by In Vitro Incubation With Heat-Killed BCG.
    Front Immunol. 2021;12:622995.
    PubMed    
    Abstract available

  103. WANG Q, Zhu SR, Huang XP, Liu XQ, et al
    Prognostic value of systemic immune-inflammation index in patients with urinary system cancers: a meta-analysis.
    Eur Rev Med Pharmacol Sci. 2021;25:1302-1310.
    PubMed    
    Abstract available

  104. CHEN L, Shan G
    CircRNA in cancer: Fundamental mechanism and clinical potential.
    Cancer Lett. 2021;505:49-57.
    PubMed    
    Abstract available

  105. NA J, Newman JA, Then CK, Syed J, et al
    SPRTN protease-cleaved MRE11 decreases DNA repair and radiosensitises cancer cells.
    Cell Death Dis. 2021;12:165.
    PubMed    
    Abstract available

  106. KATLEBA K, Lombard AP, Tsamouri MM, Baek HB, et al
    Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis.
    Cancer Lett. 2021;504:49-57.
    PubMed    
    Abstract available

  107. ACOSTA AM, Barletta J, Sonpavde G, Schnitt S, et al
    p-120 Catenin is a Useful Diagnostic Biomarker for Distinguishing Plasmacytoid and Sarcomatoid Variants From Conventional Urothelial Carcinoma.
    Arch Pathol Lab Med. 2021;145:1000-1008.
    PubMed    
    Abstract available

  108. GALVEZ-LOPEZ R, Ruiz-Carazo E, Lainez-Ramos-Bossini AJ, Garcia Salguero AJ, et al
    Miliary tuberculosis secondary to intravesical instillation of Bacillus Calmette-Guerin. Report of two cases.
    Infect Dis Now. 2021;51:213-215.
    PubMed    


  109. DUCOURS M, Desclaux A, Dutronc H, Dauchy FA, et al
    About three cases of Mycobacterium bovis bone and joint infections after BCG therapy.
    Infect Dis Now. 2021;51:211-213.
    PubMed    


  110. TAMZALI Y, Jamme M, Bottet F, Gauthe M, et al
    Intravesical BCG instillation as a possible cause of acute and chronic kidney injury.
    Infect Dis Now. 2021;51:209-211.
    PubMed    


  111. JIANG L, Zuo Z, Lin J, Yang C, et al
    Orthodenticle homeobox OTX1 is a potential prognostic biomarker for bladder cancer.
    Bioengineered. 2021;12:6559-6571.
    PubMed    
    Abstract available

  112. LEE W, Nam W, Lim B, Kyung YS, et al
    Impact of preoperative chemotherapy on pathologic nodal status in muscle-invasive bladder cancer: optimal lymphadenectomy in the preoperative chemotherapy era.
    J Cancer Res Clin Oncol. 2021 Sep 23. pii: 10.1007/s00432-021-03789.
    PubMed    
    Abstract available

  113. SUN J, Yue W, You J, Wei X, et al
    Identification of a Novel Ferroptosis-Related Gene Prognostic Signature in Bladder Cancer.
    Front Oncol. 2021;11:730716.
    PubMed    
    Abstract available

  114. COMPERAT E, Oszwald A, Wasinger G, Hansel DE, et al
    Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies.
    World J Urol. 2021 Sep 23. pii: 10.1007/s00345-021-03831.
    PubMed    
    Abstract available

  115. CAO R, Ma B, Wang G, Xiong Y, et al
    Characterization of hypoxia response patterns identified prognosis and immunotherapy response in bladder cancer.
    Mol Ther Oncolytics. 2021;22:277-293.
    PubMed    
    Abstract available

  116. HAM WS, Park JS, Jang WS, Choi YD, et al
    Prognostic value of prostate volume in non-muscle invasive bladder cancer.
    Sci Rep. 2021;11:18784.
    PubMed    
    Abstract available

  117. KRISHNA M, Kumar S, Parmar KM, Dhana Sekaran V, et al
    Unusual endophytic non-enhancing tumour in the renal pelvis: a diagnostic dilemma.
    BMJ Case Rep. 2021;14.
    PubMed    
    Abstract available

  118. ALKANLI N, Ay A, Cevik G
    Investigation of the roles of IL-18 (-607 C/A) and IL-18 (-137 G/C) gene variations in bladder cancer development: case-control study.
    J Cancer Res Clin Oncol. 2021 Sep 22. pii: 10.1007/s00432-021-03808.
    PubMed    
    Abstract available

  119. SCHULZ GB, Stief CG, Saar M, Vogeli TA, et al
    [Molecular diagnostics of bladder cancer-practical ramifications].
    Urologe A. 2021 Sep 22. pii: 10.1007/s00120-021-01640.
    PubMed    
    Abstract available

  120. MHATRE S, Lacey B, Sherliker P, Chatterjee N, et al
    Reproductive factors and gall-bladder cancer, and the effect of common genetic variants on these associations: a case-control study in India.
    Int J Epidemiol. 2021 Sep 22. pii: 6373963. doi: 10.1093.
    PubMed    
    Abstract available

  121. HEMISSI I, Ayed H, Naimi Z, Meddeb K, et al
    Polymorphisms in NQO1 and MPO genes and risk for bladder cancer in Tunisian population.
    Mol Genet Genomic Med. 2021 Sep 22:e1819. doi: 10.1002/mgg3.1819.
    PubMed    
    Abstract available

  122. QIN Z, Tong H, Li T, Cao H, et al
    SPHK1 contributes to cisplatin resistance in bladder cancer cells via the NONO/STAT3 axis.
    Int J Mol Med. 2021;48.
    PubMed    
    Abstract available

  123. HEKTOEN HH, Gislefoss RE, Stenehjem JS, Langseth H, et al
    Prediagnostic Serum 25-Hydroxyvitamin D and Mortality Among Bladder Cancer Patients in the Janus Serum Bank Cohort.
    Clin Epidemiol. 2021;13:801-811.
    PubMed    
    Abstract available

  124. GROBET-JEANDIN E, Pinar U, Roupret M
    Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for Bacillus Calmette-Guerin-unresponsive Non-muscle invasive Bladder Cancer: Con.
    Eur Urol Focus. 2021 Sep 17. pii: S2405-4569(21)00233.
    PubMed    
    Abstract available

  125. RIPPING TM, Westhoff E, Aaronson NK, Van Hemelrijck M, et al
    Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer.
    J Patient Rep Outcomes. 2021;5:96.
    PubMed    
    Abstract available

  126. ZHOU L, Wang B, Zhang Y, Yao K, et al
    Silencing circBIRC6 inhibits the proliferation, invasion, migration and epithelialmesenchymal transition of bladder cancer cells by targeting the miR4953p/XBP1 signaling axis.
    Mol Med Rep. 2021;24.
    PubMed    
    Abstract available

  127. WANG L, Liu X, Yue M, Liu Z, et al
    Identification of hub genes in bladder cancer based on weighted gene co-expression network analysis from TCGA database.
    Cancer Rep (Hoboken). 2021 Sep 20:e1557. doi: 10.1002/cnr2.1557.
    PubMed    
    Abstract available

  128. YANG Z, Xu Y, Bi Y, Zhang N, et al
    Immune escape mechanisms and immunotherapy of urothelial bladder cancer.
    J Clin Transl Res. 2021;7:485-500.
    PubMed    
    Abstract available

  129. GUO Y, Yin J, Dai Y, Guan Y, et al
    A Novel CpG Methylation Risk Indicator for Predicting Prognosis in Bladder Cancer.
    Front Cell Dev Biol. 2021;9:642650.
    PubMed    
    Abstract available

  130. GAN K, Gao Y, Liu K, Xu B, et al
    The Clinical Significance and Prognostic Value of HER2 Expression in Bladder Cancer: A Meta-Analysis and a Bioinformatic Analysis.
    Front Oncol. 2021;11:653491.
    PubMed    
    Abstract available

  131. SUN J, Wei X, You J, Yue W, et al
    STC1 is a Novel Biomarker Associated with Immune Characteristics and Prognosis of Bladder Cancer.
    Int J Gen Med. 2021;14:5505-5516.
    PubMed    
    Abstract available

  132. ARIAFAR A, Habibagahi M, Jaberipour M, Khezri A, et al
    Upregulation of Cytotoxic T-Lymphocyte-Associated Protein 4 and Forkhead Box P3 Transcripts in Peripheral Blood of Patients with Bladder Cancer.
    Iran J Med Sci. 2021;46:339-346.
    PubMed    
    Abstract available

  133. AWADALLA A, Harraz AM, Abol-Enein H, Laymon M, et al
    Prognostic influence of microsatellite alterations of muscle-invasive bladder cancer treated with radical cystectomy.
    Urol Oncol. 2021 Sep 16. pii: S1078-1439(21)00385.
    PubMed    
    Abstract available

  134. SHARMA G, Sharma A, Krishna M, Devana SK, et al
    Xpert bladder cancer monitor in surveillance of bladder cancer: Systematic review and meta-analysis.
    Urol Oncol. 2021 Sep 14. pii: S1078-1439(21)00380.
    PubMed    
    Abstract available

  135. ZHANG Y, Sun C, Tuo Z, Zhou H, et al
    Laparoscopic Cystectomy with Totally Intracorporeal Versus Extracorporeal Orthotopic Neobladder for Bladder Cancer: A Single Center Experience.
    J Laparoendosc Adv Surg Tech A. 2021 Sep 17. doi: 10.1089/lap.2021.0519.
    PubMed    
    Abstract available

  136. HUANG M, Liu L, Zhu J, Jin T, et al
    Identification of Immune-Related Subtypes and Characterization of Tumor Microenvironment Infiltration in Bladder Cancer.
    Front Cell Dev Biol. 2021;9:723817.
    PubMed    
    Abstract available

  137. ZHAO J, Zhou L, Pan Y, Chen L, et al
    A systematic review and meta-analysis of radical cystectomy in the treatment of muscular invasive bladder cancer (MIBC).
    Transl Androl Urol. 2021;10:3476-3485.
    PubMed    
    Abstract available

  138. TAN G, Wu A, Li Z, Chen G, et al
    Bioinformatics analysis based on immune-autophagy-related lncRNAs combined with immune infiltration in bladder cancer.
    Transl Androl Urol. 2021;10:3440-3455.
    PubMed    
    Abstract available

  139. LI X, Huang C, Zhang X, Yang T, et al
    Discovery of bladder cancer biomarkers in paired pre- and postoperative urine samples.
    Transl Androl Urol. 2021;10:3402-3414.
    PubMed    
    Abstract available

  140. MA T, Tian Z, Meng L, Zhang W, et al
    Young age increases the risk of lymph node positivity but improves prognosis in patients with bladder cancer treated via cystectomy: a population-based study.
    Transl Androl Urol. 2021;10:3375-3385.
    PubMed    
    Abstract available


  141. Erratum: M-ds-P21 induces cell apoptosis in bladder cancer T24 cells through P53 independent pathway.
    J Cancer Res Ther. 2021;17:1140.
    PubMed    
    Abstract available

  142. GU Y, He H, Wang M
    Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer.
    Asia Pac J Oncol Nurs. 2021;8:586-590.
    PubMed    
    Abstract available

  143. DULOVIC A, Burcul F, Culic VC, Ruscic M, et al
    Lepidium graminifolium L.: Glucosinolate Profile and Antiproliferative Potential of Volatile Isolates.
    Molecules. 2021;26.
    PubMed    
    Abstract available

  144. SHAO SP, Zhao RJ, Lu S, Wen LP, et al
    Identification of circRNA-mediated competing endogenous RNA network in the development of bladder urothelial carcinoma.
    J Biol Regul Homeost Agents. 2021;35.
    PubMed    


  145. KANG SY, Kim KM
    Highly sensitive duplex MSI test and BAT40 germline polymorphism.
    APMIS. 2021;129:607-615.
    PubMed    
    Abstract available

  146. SATHIAKUMAR N, Bolaji B, Brill I, Chen L, et al
    1,3-Butadiene, styrene and selected outcomes among synthetic rubber polymer workers: Updated exposure-response analyses.
    Chem Biol Interact. 2021;347:109600.
    PubMed    
    Abstract available

  147. LIU G, Yao Z, Chen G, Li Y, et al
    Laparoscopic compared with open nephroureterectomy in upper urinary tract urothelial carcinoma: A systemic review and a meta-analysis.
    Int J Clin Pract. 2021;75:e14639.
    PubMed    
    Abstract available

  148. PETRELLA G, Montesano C, Lentini S, Ciufolini G, et al
    Personalized Metabolic Profile by Synergic Use of NMR and HRMS.
    Molecules. 2021;26.
    PubMed    
    Abstract available

  149. NAIKI T, Nagai T, Sugiyama Y, Etani T, et al
    First Report of Oncological Outcome and Prognostic Analysis in a First-Line Setting of Short Hydration Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Urothelial Carcinoma.
    Oncology. 2021;99:622-631.
    PubMed    
    Abstract available

  150. PARMAR NV, Al Falasi A, Almualla A
    Bacillus Calmette-Guerin vaccine-induced lupus vulgaris in a 3-year-old child.
    An Bras Dermatol. 2021;96:636-638.
    PubMed    


  151. ZHOU C, Lin A, Cao M, Ding W, et al
    Activation of the DDR Pathway Leads to the Down-Regulation of the TGFbeta Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma.
    Front Immunol. 2021;12:634741.
    PubMed    
    Abstract available

  152. CHEN TJ, Chan TC, Li WS, Li CF, et al
    Utility of EFEMP1 in the Prediction of Oncologic Outcomes of Urothelial Carcinoma.
    Genes (Basel). 2021;12.
    PubMed    
    Abstract available

  153. ZHU H, Li Q, Liao T, Yin X, et al
    Metabolomic profiling of single enlarged lysosomes.
    Nat Methods. 2021;18:788-798.
    PubMed    
    Abstract available

  154. SAMARA M, Papathanassiou M, Mitrakas L, Koukoulis G, et al
    DNA Repair Gene Polymorphisms and Susceptibility to Urothelial Carcinoma in a Southeastern European Population.
    Curr Oncol. 2021;28:1879-1885.
    PubMed    
    Abstract available

  155. KIM H, Kim O, Lee MA, Lee JY, et al
    Prognostic Impact of APOBEC3B Expression in Metastatic Urothelial Carcinoma and Its Association with Tumor-Infiltrating Cytotoxic T Cells.
    Curr Oncol. 2021;28:1652-1662.
    PubMed    
    Abstract available

  156. BUSE S, Alexandrov A, Mazzone E, Mottrie A, et al
    Surgical benchmarks, mid-term oncological outcomes, and impact of surgical team composition on simultaneous enbloc robot-assisted radical cystectomy and nephroureterectomy.
    BMC Urol. 2021;21:73.
    PubMed    
    Abstract available

  157. MARCHAND M, Zhang R, Chan P, Quarmby V, et al
    Time-dependent population PK models of single-agent atezolizumab in patients with cancer.
    Cancer Chemother Pharmacol. 2021;88:211-221.
    PubMed    
    Abstract available

  158. CHEN L, Lai B, Su X, Wang J, et al
    Unusual glomus tumor of the bladder: a rare case report and literature review.
    BMC Urol. 2021;21:66.
    PubMed    
    Abstract available

  159. AICHER WK, Korn M, Reitnauer L, Maurer FB, et al
    Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma.
    BMC Urol. 2021;21:60.
    PubMed    
    Abstract available

  160. XU J, Westfall DE, Lopategui JR
    "Indeterminate" UroVysion Fluorescence In Situ Hybridization Results.
    Am J Clin Pathol. 2021;156:427-432.
    PubMed    
    Abstract available

  161. SONG YP, Mistry H, Irlam J, Valentine H, et al
    Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399).
    Int J Radiat Oncol Biol Phys. 2021;110:1407-1415.
    PubMed    
    Abstract available

  162. GAO RW, Tollefson MK, Thompson RH, Potretzke AM, et al
    Predictors of Locoregional Recurrence and Delineation of Adjuvant Radiation Therapy Fields for Patients With Upper Tract Urothelial Carcinoma Receiving Nephroureterectomy.
    Pract Radiat Oncol. 2021;11:e468-e476.
    PubMed    
    Abstract available

  163. FARAJ KS, Judge N, Chang YH, Blodgett G, et al
    Variation in Lymph Node Yield After Radical Cystectomy.
    Am J Clin Pathol. 2021;156:391-398.
    PubMed    
    Abstract available

  164. KOBAYASHI T, Toyoda T, Tajima Y, Kishimoto S, et al
    o-Anisidine Dimer, 2-Methoxy-N(4)-(2-methoxyphenyl) Benzene-1,4-diamine, in Rat Urine Associated with Urinary bladder Carcinogenesis.
    Chem Res Toxicol. 2021;34:912-919.
    PubMed    
    Abstract available

  165. CHAU C, Rimmer Frcr Y, Choudhury PhD A, Leaning Frcr D, et al
    Treatment Outcomes for Small Cell Carcinoma of the Bladder: Results From a UK Patient Retrospective Cohort Study.
    Int J Radiat Oncol Biol Phys. 2021;110:1143-1150.
    PubMed    
    Abstract available

  166. DELARA R, Wasson M, Khan A
    Bladder Leiomyoma.
    J Minim Invasive Gynecol. 2021;28:1123-1124.
    PubMed    


  167. SZEWCZYK MT, Soefje SA
    Development of an innovative delivery system for bacillus Calmette-Guerin bladder administration.
    Am J Health Syst Pharm. 2021;78:60-64.
    PubMed    
    Abstract available

  168. REY VALZACCHI GM, Pavan LI, Bourguignon GA, Cortez JP, et al
    Transvesical laparoscopy for bladder leiomyoma excision: a novel surgical technique.
    Int Urogynecol J. 2021;32:2543-2544.
    PubMed    
    Abstract available

  169. SOTELO M, Alonso-Gordoa T, Gajate P, Gallardo E, et al
    Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies.
    Clin Transl Oncol. 2021;23:882-891.
    PubMed    
    Abstract available

  170. SHI B, Qi J
    The prognostic value and potential subtypes of immune activity scores in three major urological cancers.
    J Cell Physiol. 2021;236:2620-2630.
    PubMed    
    Abstract available

  171. CLEMENT KD, Pearce E, Gabr AH, Rai BP, et al
    Perioperative outcomes and safety of robotic vs open cystectomy: a systematic review and meta-analysis of 12,640 cases.
    World J Urol. 2021;39:1733-1746.
    PubMed    
    Abstract available

  172. SU JS, Hoy NY, Fafaj A, Tastaldi L, et al
    The European Hernia Society classification applied to the rare cases of parastomal hernia after ileal conduit urinary diversion: a retrospective cohort of 96 patients.
    Hernia. 2021;25:125-131.
    PubMed    
    Abstract available

  173. GORDON NS, Baxter LA, Goel A, Arnold R, et al
    Urine dna for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: A pilot study.
    BJU Int. 2021 Sep 7. doi: 10.1111/bju.15589.
    PubMed    
    Abstract available

  174. MORTEZAVI A, Crippa A, Edeling S, Pokupic S, et al
    Morbidity and mortality after robot-assisted radical cystectomy with intracorporeal urinary diversion in octogenarians: results from the European Association of Urology Robotic Urology Section Scientific Working Group.
    BJU Int. 2021;127:585-595.
    PubMed    
    Abstract available

  175. D'ANDREA D, Matin S, Black PC, Petros FG, et al
    Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.
    BJU Int. 2021;127:528-537.
    PubMed    
    Abstract available

  176. SMITH AB, Lee JR, Lawrence SO, Lavallee DC, et al
    Patient and public involvement in the design and conduct of a large, pragmatic observational trial to investigate recurrent, high-risk non-muscle-invasive bladder cancer.
    Cancer. 2021 Sep 8. doi: 10.1002/cncr.33897.
    PubMed    
    Abstract available

  177. PARK S, Rong L, Owczarek TB, Di Bernardo M, et al
    Novel mouse models of bladder cancer identify a prognostic signature associated with risk of disease progression.
    Cancer Res. 2021 Sep 1. pii: 0008-5472.CAN-21-1254.
    PubMed    
    Abstract available

  178. YANG L, Sun J, Li M, Long Y, et al
    Oxidized low-density lipoprotein links hypercholesterolemia and bladder cancer aggressiveness by promoting cancer stemness.
    Cancer Res. 2021 Sep 3. pii: 0008-5472.CAN-21-0646.
    PubMed    
    Abstract available

  179. FUHRMAN BJ, Moore SC, Byrne C, Makhoul I, et al
    Association of the Age at Menarche with Site-Specific Cancer Risks in Pooled Data from Nine Cohorts.
    Cancer Res. 2021;81:2246-2255.
    PubMed    
    Abstract available

  180. WANG H, Mei Y, Luo C, Huang Q, et al
    Single-cell analyses reveal mechanisms of cancer stem cell maintenance and epithelial-mesenchymal transition in recurrent bladder cancer.
    Clin Cancer Res. 2021 Sep 15. pii: 1078-0432.CCR-20-4796.
    PubMed    
    Abstract available

  181. GRIMM MO, Leucht K
    Re: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
    Eur Urol. 2021;79:429-430.
    PubMed    


  182. BABJUK M, Burger M, Capoun O, Cohen D, et al
    European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
    Eur Urol. 2021 Sep 9. pii: S0302-2838(21)01978.
    PubMed    
    Abstract available

  183. JONES TD, Cheng L
    Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups.
    Eur Urol. 2021;79:489-491.
    PubMed    


  184. FUKUOKAYA W, Egawa S
    Re: Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.
    Eur Urol. 2021;79:553-554.
    PubMed    


  185. CIMADAMORE A, Lopez-Beltran A, Scarpelli M, Montironi R, et al
    Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489-91.
    Eur Urol. 2021;79:e172-e173.
    PubMed    


  186. JONES TD, Cheng L
    Reply to Alessia Cimadamore, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Sys
    Eur Urol. 2021;79:e174-e175.
    PubMed    


  187. PATEL SH, Kates M
    Open Versus Robot-assisted Radical Cystectomy: Is Standardization Without Randomization Possible?
    Eur Urol. 2021;79:619-620.
    PubMed    


  188. GAKIS G
    Re: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
    Eur Urol. 2021;79:702.
    PubMed    


  189. LEOW JJ, Chong YL, Chang SL, Valderrama BP, et al
    Reply to Alexander Andreev-Drakhlin, Jianjun Gao, Arlene Siefker-Radtke. Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma. Eur Urol 2021;79:655-6.
    Eur Urol. 2021;79:657-658.
    PubMed    


  190. ANDREEV-DRAKHLIN A, Gao J, Siefker-Radtke A
    Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma.
    Eur Urol. 2021;79:655-656.
    PubMed    


  191. LAI H, Cheng X, Liu Q, Luo W, et al
    Single-cell RNA sequencing reveals the epithelial cell heterogeneity and invasive subpopulation in human bladder cancer.
    Int J Cancer. 2021 Sep 3. doi: 10.1002/ijc.33794.
    PubMed    
    Abstract available

  192. OLAH C, Hahnen C, Nagy N, Musial J, et al
    A qPCR-based method for molecular subtype classification of urinary bladder cancer - stromal gene expressions show higher prognostic values than intrinsic tumor genes.
    Int J Cancer. 2021 Sep 18. doi: 10.1002/ijc.33809.
    PubMed    
    Abstract available

  193. GRAVESTOCK P, Coulthard N, Veeratterapillay R, Heer R, et al
    Systematic review and meta-analysis of narrow band imaging for non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Aug 27. doi: 10.1111/iju.14671.
    PubMed    
    Abstract available

  194. POLIKARPOV DM, Campbell DH, Zaslavsky AB, Lund ME, et al
    Glypican-1 as a target for fluorescence molecular imaging of bladder cancer.
    Int J Urol. 2021 Sep 8. doi: 10.1111/iju.14683.
    PubMed    
    Abstract available

  195. NASELLI A
    Editorial Comment to Systematic review and meta-analysis of narrow band imaging for non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Sep 7. doi: 10.1111/iju.14687.
    PubMed    


  196. SHARMA V, Miest TS, Juvet TS, Toussi A, et al
    The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-Analysis.
    J Urol. 2021;206:558-567.
    PubMed    
    Abstract available

  197. PETROS FG, Choi W, Qi Y, Moss T, et al
    Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma.
    J Urol. 2021;206:548-557.
    PubMed    
    Abstract available

  198. KATIMS AB, Say R, Derweesh I, Uzzo R, et al
    Risk Factors for Intravesical Recurrence after Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (ROBUUST Collaboration).
    J Urol. 2021;206:568-576.
    PubMed    
    Abstract available

  199. HENSLEY PJ, Kamat AM
    Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin: Implications for Clinical Trial Design. Reply.
    J Urol. 2021 Sep 2:101097JU0000000000002238. doi: 10.1097/JU.0000000000002238.
    PubMed    


  200. MONTORSI F, Moschini M, Necchi A, Deho F, et al
    Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guerin. Letter.
    J Urol. 2021 Sep 14:101097JU0000000000002237. doi: 10.1097/JU.0000000000002237.
    PubMed    


  201. HENSLEY PJ, Kamat AM
    Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guerin. Response.
    J Urol. 2021 Sep 14:101097JU0000000000002238. doi: 10.1097/JU.0000000000002238.
    PubMed    


  202. CARY C, Tong Y, Linsell S, Ghani K, et al
    Ranking Important Factors for Using Postoperative Chemotherapy in Non-Muscle Invasive Bladder Cancer: Conjoint Analysis Results From the Michigan Urological Surgery Improvement Collaborative (MUSIC).
    J Urol. 2021 Sep 23:101097JU0000000000002233. doi: 10.1097/JU.0000000000002233.
    PubMed    
    Abstract available

  203. WETTSTEIN MS, Baxter NN, Sutradhar R, Mamdani M, et al
    Factors Associated with Re-resection in T1 Bladder Cancer: Identifying Patients Who do Not Receive Guideline-Concordant Care at the Population Level.
    J Urol. 2021 Sep 22:101097JU0000000000002229. doi: 10.1097/JU.0000000000002229.
    PubMed    
    Abstract available

  204. GHOREIFI A, Douglawi A, Djaladat H
    The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-analysis. Letter.
    J Urol. 2021;206:1071.
    PubMed    


  205. SHARMA V, Miest TS, Chamie K, Matin SF, et al
    The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-analysis. Reply.
    J Urol. 2021;206:1072.
    PubMed    


  206. TAN P, Wang M, Zhong A, Wang Y, et al
    SRT1720 inhibits the growth of bladder cancer in organoids and murine models through the SIRT1-HIF axis.
    Oncogene. 2021 Sep 1. pii: 10.1038/s41388-021-01999.
    PubMed    
    Abstract available

  207. CHEN X, Xu R, He D, Zhang Y, et al
    CD8(+) T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer.
    Oncogene. 2021 Sep 22. pii: 10.1038/s41388-021-02019.
    PubMed    
    Abstract available

  208. LI S, Zhao Y, Chen X
    Microarray expression profile analysis of circular RNAs and their potential regulatory role in bladder carcinoma.
    Oncol Rep. 2021;45:239-253.
    PubMed    
    Abstract available

  209. CAMPAGNA J, Touzani R, Gravis G, Marino P, et al
    [Does the announcement of cancer at the time of Non Muscle-Invasive Bladder Cancer diagnosis affect quality of life and adherence of patients? Data from the French prospective cohort VICAN].
    Prog Urol. 2021 Aug 27. pii: S1166-7087(21)00213.
    PubMed    
    Abstract available

  210. SAINT F, Masson-Lecomte A
    Achieving disease free distal ureteral margin at the time of radical cystectomy: Why and for whom? (an overview of literature).
    Prog Urol. 2021;31:303-315.
    PubMed    
    Abstract available

  211. SURLEMONT L, Nouhaud FX, Dupuis H, Delcourt C, et al
    [BCG strain shortage from 2012 to 2014: Evaluation of its impact on the management of patients with high-risk NMIBC].
    Prog Urol. 2021;31:324-331.
    PubMed    
    Abstract available

  212. STRUCK JP, Hennig MJP, Hupe MC, Moharam N, et al
    Discrepancy between German S3 Guideline Recommendations and Daily Urologic Practice in the Management of Nonmuscle Invasive Bladder Cancer: Results of a Binational Survey.
    Urol Int. 2021 Aug 31:1-11. doi: 10.1159/000518166.
    PubMed    
    Abstract available

  213. YANG B, Zhao X, Wan C, Ma X, et al
    Genomic profiling of Chinese patients with urothelial carcinoma.
    BMC Cancer. 2021;21:162.
    PubMed    
    Abstract available

  214. CHAUHAN PS, Chen K, Babbra RK, Feng W, et al
    Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study.
    PLoS Med. 2021;18:e1003732.
    PubMed    
    Abstract available

  215. MUILWIJK T, Akand M, Daelemans S, Marien K, et al
    Stromal marker fibroblast activation protein drives outcome in T1 non-muscle invasive bladder cancer.
    PLoS One. 2021;16:e0257195.
    PubMed    
    Abstract available

  216. AGARWAL N, Rinaldetti S, Cheikh BB, Zhou Q, et al
    TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;